1. 2015); see also Nathan Cortez, The Statutory Case Against Off-Label Promotion, 83 U. CHICAGO L. REV;E G;Amarin Pharma, Inc. v. FDA, 119 F. Supp. 3d,2016
2. Public Health Interests and First Amendment Considerations Related to Manufacturer Communications Regarding Unapproved Uses of Approved or;E G Fda;Cleared Medical Products,2017